Hyperlipoproteinemie u dětí
[Hyperlipoproteinemia in children]
Language Czech Country Czech Republic Media print
Document type Journal Article
PubMed
28128574
PII: 60113
- MeSH
- Anticholesteremic Agents therapeutic use MeSH
- Diet Therapy MeSH
- Child MeSH
- Hyperlipoproteinemia Type II diagnosis therapy MeSH
- Hyperlipoproteinemias diagnosis therapy MeSH
- Cardiovascular Diseases MeSH
- Humans MeSH
- Adolescent MeSH
- Check Tag
- Child MeSH
- Humans MeSH
- Adolescent MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Czech Republic MeSH
- Names of Substances
- Anticholesteremic Agents MeSH
Hyperlipoproteinemia (HLP) is one of the most common metabolic disorder in childhood. We assume that 20 % of children have a disorder of the lipid metabolism. Some HLP are very common in the population, and moderate, and some are very rare, but are very severe. These may occur secondary to pathological conditions, or are formed on the basis of the primary monogenic or polygenic disorders of lipid metabolism. The detection of children with HLP in the Czech Republic is either random, or more often by selective screening of children with familial history of cardiovascular disease, provided by general pediatric practitioners for children and adolescents. Treatment in childhood is primarily dietetic, some of them, especially children with familial hypercholesterolemia are treated from 8-10 years pharmacologically.Key words: diagnosis - hyperlipoproteinemia - children - treatment.